BofA raised the firm’s price target on Eli Lilly (LLY) to $950 from $900 and keeps a Buy rating on the shares after the company reported “strong” Q3 total revenues ahead the firm and consensus by 10% and EPS ahead consensus by 23%. For 2025, the firm’s total revenue and EPS estimates are now 3% and 6% higher, respectively, while its 2026 revenue and EPS estimates increase by a low and low-to-mid single digit percentage, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly price target raised to $985 from $925 at Cantor Fitzgerald
- Eli Lilly Reports Strong Q3 2025 Growth
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Midday Fly By: Big Tech reports, Novo tops Pfizer bid for Metsera
- Morning Movers: Alphabet, Eli Lilly rise following quarterly results